Symbols / MRVI Stock $4.48 -3.86% Maravai LifeSciences Holdings, Inc.

Healthcare • Biotechnology • United States • NMS
MRVI (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Mr. Bernd Brust
Exch · Country NMS · United States
Market Cap 1.65B
Enterprise Value 994.01M
Income -104.56M
Sales 204.73M
FCF (ttm) -11.33M
Book/sh 1.43
Cash/sh 1.12
Employees 416
Insider 10d —
IPO Nov 20, 2020
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -43.20
PEG —
P/S 8.07
P/B 3.12
P/C —
EV/EBITDA -26.14
EV/Sales 4.86
Quick Ratio 4.68
Current Ratio 5.91
Debt/Eq 85.36
LT Debt/Eq —
EPS (ttm) -0.71
EPS next Y -0.10
EPS Growth —
Revenue Growth 40.50%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-05-07
Earnings (prior) 2026-05-07
ROA -6.59%
ROE -40.98%
ROIC —
Gross Margin 30.12%
Oper. Margin 1.09%
Profit Margin -51.07%
Shs Outstand 147.51M
Shs Float 98.57M
Insider Own 11.71%
Instit Own 89.18%
Short Float 7.15%
Short Ratio 4.83
Short Interest 8.88M
52W High 5.00
vs 52W High -10.31%
52W Low 1.95
vs 52W Low 129.74%
Beta 0.62
Impl. Vol. 2.80%
Rel Volume 0.32
Avg Volume 1.99M
Volume 638.46K
Target (mean) $5.70
Tgt Median $6.00
Tgt Low $5.00
Tgt High $6.00
# Analysts 5
Recom Buy
Prev Close $4.66
Price $4.48
Change -3.86%
About

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products that enable the development of drug therapies, vaccines, drug therapies, cell and gene therapies, and diagnostics North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin and Central America. It operates through two segments: TRILINK and CYGNUS. The TRILINK segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, and oligonucleotide therapy, as well as molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, CleanCap capping technology-based oligonucleotide building blocks, and custom enzyme development and manufacturing; and research products for labeling and detecting proteins in cells and tissue samples. The CYGNUS segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, and antibody-based products to detect impurities during the production of biopharmaceutical products. It serves biopharmaceutical companies, and emerging biopharmaceutical and life sciences research companies; and academic research institutions and diagnostics companies. Maravai LifeSciences Holdings, Inc. was founded in 2014 and is headquartered in San Diego, California.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$5.70
Mean price target
2. Current target
$4.48
Latest analyst target
3. DCF / Fair value
$-1.38
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$4.48
Low
$5.00
High
$6.00
Mean
$5.70

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-05-08 main Wells Fargo Overweight → Overweight $6
2025-12-15 main Wells Fargo Overweight → Overweight $5
2025-08-12 main RBC Capital Outperform → Outperform $5
2025-08-12 main Craig-Hallum Buy → Buy $5
2025-05-13 main Craig-Hallum Buy → Buy $10
2025-05-13 main Baird Neutral → Neutral $2
2025-03-25 main Morgan Stanley Equal-Weight → Equal-Weight $5
2025-03-21 main UBS Neutral → Neutral $3
2025-03-03 main B of A Securities Buy → Buy $8
2025-02-26 down Baird Outperform → Neutral $3
2024-12-05 down Goldman Sachs Neutral → Sell $4
2024-11-14 init Wolfe Research — → Peer Perform —
2024-11-08 main RBC Capital Outperform → Outperform $13
2024-11-08 down William Blair Outperform → Market Perform —
2024-11-08 main Baird Outperform → Outperform $9
2024-10-08 main Goldman Sachs Neutral → Neutral $7
2024-08-27 init Wells Fargo — → Overweight $10
2024-08-16 reit RBC Capital Outperform → Outperform $15
2024-08-13 down Morgan Stanley Overweight → Equal-Weight $10
2024-08-08 main Goldman Sachs Neutral → Neutral $8
News
RSS: Latest MRVI news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2025-12-08 LUCIER GREGORY T Director — 100,000 $3.67 $368,544
2025-11-14 DOLAN CHRISTINE Officer — 4,300 $3.64 $15,652
2025-11-13 BRUST BERND Chief Executive Officer — 216,212 $3.25 $702,689
2025-11-12 BRUST BERND Chief Executive Officer — 250,559 $3.21 $809,010
2025-07-10 LUCIER GREGORY T Director — 89,139 $0.00 $0
2025-06-30 ASARPOTA RAJESH J Chief Financial Officer — 500,000 $0.00 $0
2025-06-16 ECKERT ROBERT ANDREW Director — 231,481 $2.16 $499,999
2025-06-16 DEFORD JOHN A Director — 89,139 $2.16 $192,540
2025-06-16 HOPFIELD JESSICA Director — 89,139 $2.16 $192,540
2025-06-16 PRAHALAD MURALI K Director — 89,139 $2.16 $192,540
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
185.74
-28.34%
259.19
-10.30%
288.94
-67.28%
883.00
Operating Revenue
185.74
-28.34%
259.19
-10.30%
288.94
-67.28%
883.00
Cost Of Revenue
151.75
+0.58%
150.88
+1.43%
148.74
-11.96%
168.96
Reconciled Cost Of Revenue
151.75
+0.58%
150.88
+1.43%
148.74
-11.96%
168.96
Gross Profit
33.99
-68.62%
108.31
-22.75%
140.20
-80.37%
714.04
Operating Expense
162.52
-10.21%
180.99
+7.31%
168.67
+14.25%
147.63
Research And Development
17.40
-9.46%
19.22
+11.23%
17.28
-5.93%
18.37
Selling General And Administration
145.12
-10.29%
161.77
+6.86%
151.39
+17.12%
129.26
Total Expenses
314.27
-5.30%
331.87
+4.55%
317.41
+0.26%
316.58
Operating Income
-128.53
-76.84%
-72.68
-155.31%
-28.47
-105.03%
566.42
Total Operating Income As Reported
-215.27
+8.64%
-235.62
-644.49%
-31.65
-105.51%
574.22
EBITDA
-147.51
+5.99%
-156.92
-122.03%
712.41
+16.79%
609.99
Normalized EBITDA
-60.77
-760.30%
9.20
-98.71%
715.59
+18.79%
602.40
Reconciled Depreciation
60.47
+6.34%
56.87
+16.57%
48.78
+28.02%
38.10
EBIT
-207.98
+2.71%
-213.78
-132.21%
663.63
+16.04%
571.89
Total Unusual Items
-86.74
+47.79%
-166.12
-5123.93%
-3.18
-141.89%
7.59
Total Unusual Items Excluding Goodwill
-86.74
+47.79%
-166.12
-5123.93%
-3.18
-141.89%
7.59
Special Income Charges
-86.74
+47.79%
-166.12
-5123.93%
-3.18
-141.89%
7.59
Other Special Charges
—
3.19
—
0.21
Impairment Of Capital Assets
68.71
-58.65%
166.15
0.00
0.00
Restructuring And Mergern Acquisition
18.03
+660.37%
-3.22
-201.16%
3.18
+140.77%
-7.80
Net Income
-130.77
+9.72%
-144.85
-21.69%
-119.03
-154.05%
220.21
Pretax Income
-234.97
+10.14%
-261.48
-142.33%
617.74
+12.02%
551.47
Net Non Operating Interest Income Expense
-15.56
+23.36%
-20.30
-11.74%
-18.16
-0.49%
-18.08
Interest Expense Non Operating
26.99
-43.41%
47.70
+3.94%
45.89
+124.81%
20.41
Net Interest Income
-15.56
+23.36%
-20.30
-11.74%
-18.16
-0.49%
-18.08
Interest Expense
26.99
-43.41%
47.70
+3.94%
45.89
+124.81%
20.41
Interest Income Non Operating
11.44
-58.27%
27.40
-1.17%
27.73
+1085.93%
2.34
Interest Income
11.44
-58.27%
27.40
-1.17%
27.73
+1085.93%
2.34
Other Income Expense
-90.89
+46.06%
-168.50
-125.36%
664.37
+21112.29%
3.13
Other Non Operating Income Expenses
-4.15
-74.38%
-2.38
-100.36%
667.55
+15067.47%
-4.46
Gain On Sale Of Business
—
—
0.00
0.00
Tax Provision
-4.21
-126.45%
-1.86
-100.25%
756.11
+1143.42%
60.81
Tax Rate For Calcs
0.00
+157.14%
0.00
-96.67%
0.00
+90.91%
0.00
Tax Effect Of Unusual Items
-1.56
-34.26%
-1.16
-74.13%
-0.67
-179.96%
0.84
Net Income Including Noncontrolling Interests
-230.76
+11.12%
-259.62
-87.62%
-138.38
-128.20%
490.66
Net Income From Continuing Operation Net Minority Interest
-130.77
+9.72%
-144.85
-21.69%
-119.03
-154.05%
220.21
Net Income From Continuing And Discontinued Operation
-130.77
+9.72%
-144.85
-21.69%
-119.03
-154.05%
220.21
Net Income Continuous Operations
-230.76
+11.12%
-259.62
-87.62%
-138.38
-128.20%
490.66
Minority Interests
99.99
-12.88%
114.78
+493.28%
19.35
+107.15%
-270.46
Normalized Income
-45.60
-326.72%
20.11
+117.26%
-116.52
-154.59%
213.45
Net Income Common Stockholders
-130.77
+9.72%
-144.85
-21.69%
-119.03
-154.05%
220.21
Diluted EPS
—
-1.05
-16.67%
-0.90
-153.89%
1.67
Basic EPS
—
-1.05
-16.67%
-0.90
-153.89%
1.67
Basic Average Shares
—
137.91
+4.54%
131.92
+0.28%
131.54
Diluted Average Shares
—
137.91
+4.54%
131.92
-48.33%
255.32
Diluted NI Availto Com Stockholders
-130.77
+9.72%
-144.85
-21.69%
-119.03
-127.92%
426.28
Average Dilution Earnings
—
0.00
0.00
-100.00%
206.07
Gain On Sale Of PPE
—
—
—
0.00
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
770.58
-23.57%
1,008.24
-32.22%
1,487.45
-34.83%
2,282.32
Current Assets
296.25
-30.97%
429.15
-38.69%
699.91
-17.45%
847.90
Cash Cash Equivalents And Short Term Investments
216.89
-32.73%
322.40
-43.93%
574.96
-9.04%
632.14
Cash And Cash Equivalents
216.89
-32.73%
322.40
-43.93%
574.96
-9.04%
632.14
Cash Financial
216.89
-32.73%
322.40
-43.93%
574.96
-9.04%
632.14
Receivables
25.50
-33.81%
38.52
-29.46%
54.60
-62.81%
146.81
Accounts Receivable
25.50
-33.81%
38.52
-29.46%
54.60
-60.61%
138.62
Gross Accounts Receivable
—
41.72
-25.51%
56.01
-60.23%
140.82
Allowance For Doubtful Accounts Receivable
—
-3.20
-128.57%
-1.40
+36.36%
-2.20
Other Receivables
—
—
1.12
-86.35%
8.19
Inventory
40.49
-19.14%
50.08
-2.56%
51.40
+19.11%
43.15
Raw Materials
14.61
-13.95%
16.97
-12.22%
19.34
+43.39%
13.49
Work In Process
7.32
-27.18%
10.05
-20.74%
12.68
-42.23%
21.95
Finished Goods
18.57
-19.46%
23.06
+18.98%
19.38
+151.15%
7.72
Prepaid Assets
—
—
—
—
Other Current Assets
13.37
-26.33%
18.14
-4.24%
18.95
-26.55%
25.80
Total Non Current Assets
474.33
-18.09%
579.10
-26.47%
787.54
-45.10%
1,434.41
Net PPE
190.74
-12.11%
217.03
-2.52%
222.65
+90.96%
116.59
Gross PPE
258.82
-4.05%
269.73
+5.84%
254.86
+87.27%
136.09
Accumulated Depreciation
-68.08
-29.17%
-52.71
-63.62%
-32.21
-65.18%
-19.50
Properties
0.00
0.00
0.00
0.00
Land And Improvements
—
—
—
—
Buildings And Improvements
—
—
—
—
Machinery Furniture Equipment
87.03
+12.69%
77.23
+48.51%
52.00
+33.65%
38.91
Construction In Progress
14.68
-38.22%
23.76
-40.05%
39.64
+200.51%
13.19
Other Properties
117.86
-10.13%
131.15
-5.20%
138.34
+116.52%
63.90
Leases
39.25
+4.42%
37.59
+51.11%
24.87
+23.78%
20.09
Goodwill And Other Intangible Assets
280.97
-20.82%
354.83
-35.13%
547.02
+3.68%
527.58
Goodwill
129.43
-19.05%
159.88
-50.96%
326.03
+14.93%
283.67
Other Intangible Assets
151.54
-22.27%
194.96
-11.78%
220.99
-9.40%
243.92
Non Current Deferred Assets
—
—
0.00
-100.00%
765.80
Non Current Deferred Taxes Assets
—
—
0.00
-100.00%
765.80
Non Current Prepaid Assets
—
—
—
27.25
Other Non Current Assets
2.62
-63.87%
7.24
-59.51%
17.88
-26.86%
24.44
Total Liabilities Net Minority Interest
397.87
-7.70%
431.04
-38.21%
697.57
-49.34%
1,377.07
Current Liabilities
44.92
-21.16%
56.97
-34.87%
87.47
-20.59%
110.14
Payables And Accrued Expenses
14.73
-30.74%
21.27
-60.00%
53.17
-16.67%
63.81
Payables
3.65
-71.33%
12.74
-32.25%
18.80
-61.85%
49.27
Accounts Payable
2.91
-75.66%
11.96
+11.45%
10.73
+79.09%
5.99
Other Payable
—
—
—
—
Current Accrued Expenses
11.08
+29.84%
8.53
-75.18%
34.37
+136.47%
14.54
Pensionand Other Post Retirement Benefit Plans Current
11.11
-35.29%
17.16
+32.99%
12.90
-35.06%
19.87
Total Tax Payable
0.74
-4.75%
0.78
-22.18%
1.00
-2.72%
1.03
Current Debt And Capital Lease Obligation
14.20
+3.56%
13.71
+6.69%
12.85
+9.77%
11.71
Current Debt
5.44
+0.00%
5.44
+0.00%
5.44
+0.00%
5.44
Other Current Borrowings
5.44
+0.00%
5.44
+0.00%
5.44
+0.00%
5.44
Current Capital Lease Obligation
8.76
+5.90%
8.27
+11.60%
7.41
+18.25%
6.27
Current Deferred Liabilities
2.99
-9.07%
3.29
-40.45%
5.52
+16.05%
4.75
Current Deferred Revenue
2.99
-9.07%
3.29
-40.45%
5.52
+16.05%
4.75
Other Current Liabilities
1.89
+22.68%
1.54
-48.97%
3.02
-69.76%
10.00
Total Non Current Liabilities Net Minority Interest
352.95
-5.64%
374.06
-38.69%
610.10
-51.84%
1,266.93
Long Term Debt And Capital Lease Obligation
350.51
-3.44%
362.98
-39.31%
598.11
+4.28%
573.55
Long Term Debt
286.33
-1.43%
290.49
-44.00%
518.71
-0.63%
522.00
Long Term Capital Lease Obligation
64.18
-11.47%
72.49
-8.71%
79.41
+54.02%
51.56
Tradeand Other Payables Non Current
0.00
-100.00%
4.08
-36.10%
6.39
-16.84%
7.68
Non Current Deferred Liabilities
2.25
+20309.09%
0.01
—
—
Non Current Deferred Taxes Liabilities
2.25
+20309.09%
0.01
—
—
Other Non Current Liabilities
0.20
-52.18%
0.41
-82.79%
2.39
+479.66%
0.41
Stockholders Equity
212.38
-34.71%
325.29
-21.95%
416.75
-23.56%
545.22
Common Stock Equity
212.38
-34.71%
325.29
-21.95%
416.75
-23.56%
545.22
Capital Stock
2.56
+1.31%
2.53
+0.56%
2.51
-1.61%
2.55
Common Stock
2.56
+1.31%
2.53
+0.56%
2.51
-1.61%
2.55
Share Issued
145.32
+2.36%
141.98
+7.37%
132.23
+0.41%
131.69
Ordinary Shares Number
145.32
+2.36%
141.98
+7.37%
132.23
+0.41%
131.69
Additional Paid In Capital
199.18
+9.51%
181.87
+41.53%
128.50
-6.81%
137.90
Retained Earnings
10.12
-92.82%
140.89
-50.69%
285.74
-29.41%
404.77
Gains Losses Not Affecting Retained Earnings
0.52
0.00
—
—
Minority Interest
160.33
-36.36%
251.92
-32.49%
373.13
+3.64%
360.02
Other Equity Adjustments
0.52
—
—
—
Total Equity Gross Minority Interest
372.71
-35.43%
577.21
-26.92%
789.88
-12.74%
905.24
Total Capitalization
498.71
-19.01%
615.78
-34.17%
935.46
-12.35%
1,067.21
Working Capital
251.33
-32.47%
372.18
-39.23%
612.44
-16.99%
737.76
Invested Capital
504.15
-18.85%
621.22
-33.98%
940.90
-12.28%
1,072.65
Total Debt
364.71
-3.18%
376.69
-38.34%
610.97
+4.39%
585.26
Net Debt
74.88
—
—
—
Capital Lease Obligations
72.94
-9.69%
80.76
-6.98%
86.82
+50.14%
57.83
Net Tangible Assets
-68.59
-132.18%
-29.54
+77.32%
-130.26
-838.70%
17.63
Tangible Book Value
-68.59
-132.18%
-29.54
+77.32%
-130.26
-838.70%
17.63
Dueto Related Parties Current
—
0.00
-100.00%
7.07
-83.27%
42.25
Dueto Related Parties Non Current
—
—
0.00
-100.00%
675.96
Interest Payable
4.04
-11.45%
4.57
-50.38%
9.20
+19.51%
7.70
Non Current Accrued Expenses
0.00
-100.00%
6.58
+105.50%
3.20
-65.66%
9.32
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-57.57
-871.24%
7.46
-94.09%
126.22
-76.45%
535.98
Cash Flow From Continuing Operating Activities
-57.57
-871.24%
7.46
-94.09%
126.22
-76.45%
535.98
Net Income From Continuing Operations
-230.76
+11.12%
-259.62
-87.62%
-138.38
-128.20%
490.66
Depreciation Amortization Depletion
60.47
+6.34%
56.87
+16.57%
48.78
+28.02%
38.10
Depreciation
32.52
+10.86%
29.33
+36.91%
21.43
+54.87%
13.83
Amortization Cash Flow
27.95
+1.53%
27.53
+0.64%
27.36
+12.72%
24.27
Depreciation And Amortization
60.47
+6.34%
56.87
+16.57%
48.78
+28.02%
38.10
Amortization Of Intangibles
27.95
+1.53%
27.53
+0.64%
27.36
+12.72%
24.27
Other Non Cash Items
1.87
+5.66%
1.77
+100.26%
-672.85
-7172.47%
-9.25
Stock Based Compensation
30.17
-38.94%
49.41
+42.87%
34.59
+85.26%
18.67
Asset Impairment Charge
84.60
-49.08%
166.15
0.00
0.00
Deferred Tax
4.06
+75.31%
2.32
-99.69%
756.24
+1672.41%
42.67
Deferred Income Tax
4.06
+75.31%
2.32
-99.69%
756.24
+1672.41%
42.67
Operating Gains Losses
—
3.19
—
0.21
Gain Loss On Sale Of PPE
—
—
—
0.00
Change In Working Capital
-7.98
+36.72%
-12.61
-112.89%
97.84
+317.04%
-45.08
Change In Receivables
12.82
-10.75%
14.36
-82.99%
84.39
+478.93%
-22.27
Changes In Account Receivables
12.82
-10.75%
14.36
-82.99%
84.39
+478.93%
-22.27
Change In Inventory
8.00
+2021.75%
0.38
-41.91%
0.65
-93.14%
9.46
Change In Prepaid Assets
1.63
-10.31%
1.81
-75.08%
7.28
+120.26%
-35.90
Change In Payables And Accrued Expense
-11.97
+47.98%
-23.02
-211.51%
20.64
+198.08%
6.92
Change In Accrued Expense
-4.63
+80.51%
-23.74
-254.58%
15.36
+80.62%
8.50
Change In Payable
-7.35
-1116.18%
0.72
-86.32%
5.28
+434.85%
-1.58
Change In Account Payable
-7.35
-1116.18%
0.72
-86.32%
5.28
+434.85%
-1.58
Change In Other Working Capital
—
-0.99
-494.40%
0.25
+103.51%
-7.12
Change In Other Current Assets
0.18
+18.30%
0.15
-82.23%
0.86
—
Change In Other Current Liabilities
-18.63
-195.78%
-6.30
+60.58%
-15.98
-517.29%
3.83
Investing Cash Flow
-31.41
-29.15%
-24.32
+80.12%
-122.31
+54.30%
-267.61
Cash Flow From Continuing Investing Activities
-31.41
-29.15%
-24.32
+80.12%
-122.31
+54.30%
-267.61
Net PPE Purchase And Sale
-12.41
+44.86%
-22.52
+57.27%
-52.69
-229.61%
-15.98
Purchase Of PPE
-13.15
+55.66%
-29.66
+54.76%
-65.55
-283.58%
-17.09
Sale Of PPE
0.73
-89.72%
7.14
-44.49%
12.87
+1064.25%
1.10
Capital Expenditure
-13.15
+55.66%
-29.66
+54.76%
-65.55
-283.58%
-17.09
Net Business Purchase And Sale
-18.99
0.00
+100.00%
-69.62
+70.79%
-238.35
Purchase Of Business
-18.99
0.00
+100.00%
-69.62
+70.87%
-238.97
Gain Loss On Sale Of Business
—
—
0.00
0.00
Net Intangibles Purchase And Sale
—
-1.50
0.00
0.00
Purchase Of Intangibles
—
-1.50
0.00
0.00
Net Other Investing Changes
—
-1.80
—
-13.28
Financing Cash Flow
-16.50
+93.00%
-235.71
-285.84%
-61.09
+67.42%
-187.50
Cash Flow From Continuing Financing Activities
-16.50
+93.00%
-235.71
-285.84%
-61.09
+67.42%
-187.50
Net Issuance Payments Of Debt
-5.44
+97.68%
-234.39
-4208.69%
-5.44
+0.00%
-5.44
Issuance Of Debt
—
0.95
0.00
-100.00%
8.46
Repayment Of Debt
-5.44
+97.68%
-234.39
-4208.69%
-5.44
+60.85%
-13.89
Long Term Debt Issuance
—
0.95
0.00
-100.00%
8.46
Long Term Debt Payments
-5.44
+97.68%
-234.39
-4208.69%
-5.44
+60.85%
-13.89
Net Long Term Debt Issuance
-5.44
+97.68%
-234.39
-4208.69%
-5.44
+0.00%
-5.44
Net Common Stock Issuance
—
—
—
0.00
Common Stock Payments
—
—
—
0.00
Repurchase Of Capital Stock
—
—
—
0.00
Proceeds From Stock Option Exercised
—
-2.08
-10310.00%
-0.02
-100.85%
2.36
Net Other Financing Charges
-11.06
-738.44%
-1.32
+97.63%
-55.65
+69.82%
-184.42
Changes In Cash
-105.48
+58.24%
-252.56
-341.73%
-57.18
-170.70%
80.87
Effect Of Exchange Rate Changes
-0.03
0.00
0.00
0.00
Beginning Cash Position
322.40
-43.93%
574.96
-9.04%
632.14
+14.67%
551.27
End Cash Position
216.89
-32.73%
322.40
-43.93%
574.96
-9.04%
632.14
Free Cash Flow
-70.72
-218.67%
-22.19
-136.58%
60.67
-88.31%
518.89
Interest Paid Supplemental Data
24.98
-51.00%
50.97
+15.18%
44.26
+119.11%
20.20
Income Tax Paid Supplemental Data
—
0.67
—
23.03
Common Stock Issuance
—
—
—
0.00
Issuance Of Capital Stock
—
—
—
0.00
Sale Of Business
—
0.00
0.00
-100.00%
0.62
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category